Regulation of the androgen receptor in human genital skin fibroblasts, with a review of sex steroid receptor regulation by homologous and heterologous steroids

1983 ◽  
Vol 61 (7) ◽  
pp. 770-778 ◽  
Author(s):  
Leonard Pinsky ◽  
Morris Kaufman ◽  
Carmen Gil-Esteban ◽  
Datevik Sumbulian

When normal human genital skin fibroblasts are cultured for 3 days with 2–3 nM methyltrienolone (R1881, a synthetic nonmetabolizable androgen), they augment their specific androgen-receptor activity (two- to four-fold) with a time pattern that is always most rapid in the first 24 h, usually peaks by 48 h, and often declines, sometimes substantially, in the third 24-h interval. The time pattern is highly reproducible within experiments on confluent monolayers and is not influenced by the presence or absence of 10% fetal calf serum in the medium, the temperature (37 vs. 40 °C) at which the incubation is conducted, or the basal activity (up to 40 fmol/mg protein) that is saturated by incubation for 30–45 min at 37 °C. It does appear to be influenced by an unusually rapid increase in the first 24 h and by nonconfluent density of the monolayers, but these factors do not explain the considerable interexperimental variation, within and among cell lines, under nominally identical conditions. The time pattern is interpreted to represent an initial phase of "up-regulation" that is followed by one of compensatory adjustment, despite a constant level of unmetabolized ligand. A review of sex steroid receptor regulation by homologous and heterologous sex steroids reveals numerous examples of apparently homologous regulatory behavior.

2001 ◽  
Vol 173 (1-2) ◽  
pp. 135-145 ◽  
Author(s):  
Michelle S. Cotroneo ◽  
Jun Wang ◽  
Isam-Eldin A. Eltoum ◽  
Coral A. Lamartiniere

Author(s):  
Balkees Abderrahman ◽  
V. Craig Jordan

Breast and prostate cancer cells are regulated by sex steroids through their nuclear receptors. These receptor-positive cells are a major component of both cancers. The discovery of sex-steroid receptor regulation in breast, uterine, and prostate cancer has provided the most important targets in cancer therapeutics. This targeted therapeutic approach resulted in the enhanced survival of millions of patients worldwide. The biology of sex-steroid receptor regulation is discussed and individual therapeutic strategies are described. The molecular biology of acquired drug resistance in breast and prostate cancer is compared. Information linking mutations of sex-steroid receptors with acquired drug resistance is noted, as this is influencing future drug discovery with selective oestrogen receptor downregulators (SERDs). Current clinical approaches to subvert acquired drug resistance in breast and prostate cancer are also summarized.


1986 ◽  
Vol 113 (1_Suppl) ◽  
pp. S152
Author(s):  
M. BREINER ◽  
G. ROMALO ◽  
H.U. SCHWEIKERT

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Diana Trnski ◽  
Maja Sabol ◽  
Sanja Tomić ◽  
Ivan Štefanac ◽  
Milanka Mrčela ◽  
...  

AbstractProstate cancer is the second most frequent cancer diagnosed in men worldwide. Localized disease can be successfully treated, but advanced cases are more problematic. After initial effectiveness of androgen deprivation therapy, resistance quickly occurs. Therefore, we aimed to investigate the role of Hedgehog-GLI (HH-GLI) signaling in sustaining androgen-independent growth of prostate cancer cells. We found various modes of HH-GLI signaling activation in prostate cancer cells depending on androgen availability. When androgen was not deprived, we found evidence of non-canonical SMO signaling through the SRC kinase. After short-term androgen deprivation canonical HH-GLI signaling was activated, but we found little evidence of canonical HH-GLI signaling activity in androgen-independent prostate cancer cells. We show that in androgen-independent cells the pathway ligand, SHH-N, non-canonically binds to the androgen receptor through its cholesterol modification. Inhibition of this interaction leads to androgen receptor signaling downregulation. This implies that SHH-N activates the androgen receptor and sustains androgen-independence. Targeting this interaction might prove to be a valuable strategy for advanced prostate cancer treatment. Also, other non-canonical aspects of this signaling pathway should be investigated in more detail and considered when developing potential therapies.


2006 ◽  
Vol 84 (8) ◽  
pp. 651-659 ◽  
Author(s):  
U. Hoppe ◽  
P.-M. Holterhus ◽  
L. Wünsch ◽  
D. Jocham ◽  
T. Drechsler ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document